Your browser is no longer supported. Please, upgrade your browser.
We’ve released a new Beta version of our Futures section! Try it now. We look forward to your feedback! ×
Settings
SRPT [NASD]
Sarepta Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.38 Insider Own0.50% Shs Outstand41.31M Perf Week1.36%
Market Cap554.38M Forward P/E- EPS next Y-3.26 Insider Trans0.78% Shs Float37.96M Perf Month3.23%
Income-135.80M PEG- EPS next Q-1.00 Inst Own60.00% Short Float32.69% Perf Quarter10.18%
Sales9.80M P/S56.57 EPS this Y-2.40% Inst Trans-1.55% Short Ratio16.22 Perf Half Y-39.79%
Book/sh5.99 P/B2.24 EPS next Y22.60% ROA-44.30% Target Price25.31 Perf Year-64.86%
Cash/sh5.09 P/C2.63 EPS next 5Y-0.20% ROE-51.10% 52W Range11.33 - 38.77 Perf YTD-7.26%
Dividend- P/FCF- EPS past 5Y-15.90% ROI-53.10% 52W High-65.39% Beta0.91
Dividend %- Quick Ratio6.70 Sales past 5Y-11.10% Gross Margin- 52W Low18.45% ATR0.57
Employees204 Current Ratio6.70 Sales Q/Q-99.00% Oper. Margin- RSI (14)43.63 Volatility3.92% 4.34%
OptionableYes Debt/Eq0.02 EPS Q/Q-365.20% Profit Margin- Rel Volume0.36 Prev Close13.66
ShortableYes LT Debt/Eq0.01 EarningsMay 28 BMO Payout- Avg Volume765.26K Price13.42
Recom2.40 SMA20-2.63% SMA50-3.02% SMA200-21.50% Volume273,347 Change-1.76%
Mar-02-15Reiterated Needham Buy $52 → $38
Jan-23-15Initiated RBC Capital Mkts Sector Perform $15
Nov-26-14Upgrade WBB Securities Buy → Strong Buy $25 → $25
Oct-28-14Downgrade Robert W. Baird Outperform → Neutral $53 → $21
Aug-01-14Initiated Oppenheimer Outperform $45
Jul-29-14Upgrade WBB Securities Speculative Buy → Buy $25
Apr-22-14Reiterated Needham Buy $36 → $52
Apr-22-14Reiterated Deutsche Bank Hold $17 → $35
Mar-04-14Reiterated Canaccord Genuity Hold $25 → $27
Jan-21-14Upgrade Needham Hold → Buy $36
Nov-26-13Upgrade WBB Securities Sell → Speculative Buy $9 → $19
Nov-13-13Downgrade Needham Buy → Hold
Nov-13-13Downgrade Deutsche Bank Buy → Hold $71 → $17
Nov-12-13Reiterated FBR Capital Mkt Perform $48 → $20
Oct-30-13Initiated FBR Capital Mkt Perform $48
Sep-06-13Initiated Stifel Buy $51
Apr-22-13Initiated Needham Buy $57
Apr-04-13Initiated Robert W. Baird Outperform $63
Apr-03-13Initiated Robert W. Baird Outperform $63
Mar-08-13Reiterated Burrill Institutional Research Mkt Outperform $54 → $39
Apr-23-15 10:01AM  Santhera -- A Duchenne Drug With Positive Study Results That Few Know About at TheStreet
Apr-20-15 05:29PM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events
Apr-13-15 11:10AM  Tekmira Up on Ebola Candidate Update from the FDA - Analyst Blog
Apr-06-15 01:26PM  4 Stocks Rising on Unusual Volume to Trade for Breakouts at TheStreet
Apr-02-15 04:57PM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex
Apr-01-15 06:36PM  Sarepta CEO Exits, Eteplirsen Regulatory Filing on Track - Analyst Blog +7.61%
05:35PM  Stock Pops & Drops: SRPT, KORS, DAL & GPRO
02:32PM  Sarepta Therapeutics CEO Resigns Amid Tumult With the FDA at The Wall Street Journal
10:24AM  Sarepta Therapeutics: Why CEO Resignation is Good News at Barrons.com
10:07AM  Sarepta CEO Quits; Successor Pledges to Work Better With FDA at Bloomberg
09:16AM  Stock Futures Down, Not Diving; Jobs Data Slip To 11-Month Low at Investor's Business Daily
08:54AM  Sarepta Therapeutics CEO Chris Garabedian resigns at MarketWatch
08:28AM  Sarepta shares rally 10% as company names interim CEO at MarketWatch
08:00AM  Sarepta Therapeutics Inc. Appoints Edward Kaye, M.D., as Interim CEO and Management Update Call scheduled for 8:00 am ET today
07:47AM  Early movers: SHLD, WMT, GDDY, AAPL & more at CNBC
Mar-31-15 10:35PM  An Interview With Sarepta's New CEO at Forbes
09:57PM  Sudden Exit of Sarepta CEO Fuels Speculation That Soured FDA Relationship Is to Blame at TheStreet
08:33PM  Sarepta Therapeutics Appoints Edward Kaye, M.D., as Interim CEO; Company on Track with Clinical and Regulatory Plans for Investigational Duchenne Muscular Dystrophy Drugs at noodls
08:08PM  Sarepta Therapeutics Appoints Edward Kaye, M.D., as Interim CEO; Company on Track with Clinical and Regulatory Plans for Investigational Duchenne Muscular Dystrophy Drugs Business Wire
Mar-26-15 02:50PM  MassBio panel tackles perils of drugs for bioterrorism and superbugs at bizjournals.com
Mar-24-15 10:14PM  Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2014 Financial Results and Recent Corporate Developments at noodls
Mar-23-15 09:52PM  Sarepta Therapeutics' 3 Biggest Risks at Investopedia
Mar-19-15 11:03AM  Amicus Up As FDA, EU Green-light Quick Drug Filings at Investor's Business Daily
Mar-18-15 02:09PM  This Upcoming Event Could Affect Sarepta Therapeutics Investors
08:16AM  FDA panel to discuss Ebola vaccine development in May Reuters
Mar-17-15 10:40AM  Emergent BioSolutions Inks Deals for Its Ebola Vaccine - Analyst Blog
Mar-05-15 01:04PM  SAREPTA THERAPEUTICS, INC. Financials
Mar-02-15 06:15PM  Should We Be Concerned For Sareptas Share Prices? at Investopedia
Mar-01-15 10:19AM  ZMapp Ebola Trial Starts In Liberia: Is It Too Late? at Forbes
Feb-27-15 12:50PM  U.S., Liberia kick off trial of Ebola drug ZMapp
Feb-26-15 08:00AM  Sarepta Therapeutics Inc Earnings Call scheduled for 8:00 am ET today -7.81%
07:57AM  Sarepta Therapeutics reports 4Q loss
07:11AM  SAREPTA THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
07:11AM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
07:07AM  Q4 2014 Sarepta Therapeutics Inc Earnings Release - Before Market Open
07:00AM  Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2014 Financial Results and Recent Corporate Developments Business Wire
Feb-24-15 03:40PM  Will Aegerion (AEGR) Miss Earnings Estimates This Season? - Analyst Blog Zacks
10:47AM  Medicago wins contract to develop Ebola treatments Reuters
08:30AM  Sarepta Therapeutics to Present Company Overview at Upcoming Conferences Business Wire
Feb-23-15 04:20PM  Will BioMarin (BMRN) Beat Estimates this Earnings Season? - Analyst Blog Zacks
02:30PM  Will Exelixis (EXEL) Miss Estimates this Earnings Season? - Analyst Blog Zacks
Feb-19-15 04:59PM  Why Muscular Dystrophy Is Biotech's Favorite Orphan at Investor's Business Daily
08:30AM  Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2014 Financial Results and Corporate Update on February 26, 2015 Business Wire
Feb-17-15 03:01PM  Why 1 Analyst Sees Over 50% Upside in Sarepta at 24/7 Wall St. +15.13%
01:54PM  Bank Of America Upgrades Sarepta Therapeutics On 'Increased Conviction' Of Drug Approval Benzinga
12:48PM  Not Too Late to Ride on Q4 Earnings: 3 Biotech Picks - Earnings ESP Zacks
09:00AM  Morning Movers: Medtronic Gains on Earnings Beat; Sarepta Jumps on Merrill Upgrade at Barrons.com
Feb-04-15 08:30AM  Sarepta Therapeutics to Present Company Overview at Upcoming Conferences Business Wire
Jan-30-15 10:32AM  INVESTOR ALERT: Class Action Lawsuit Against Sarepta Therapeutics, Inc. Announced by Law Offices of Howard G. Smith Business Wire
Jan-29-15 09:02AM  UPDATE - SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Sarepta Therapeutics, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of February 6, 2015 -- SRPT GlobeNewswire
Jan-27-15 07:00AM  Sarepta Therapeutics, Inc. (SRPT): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report Zacks
Jan-26-15 06:40PM  ALERT: Rosen Law Firm Reminds Sarepta Therapeutics Investors of Important February 9, 2015 Deadline in Class Action Seeking to Recover Investor Losses -- SRPT GlobeNewswire
Jan-23-15 06:24AM  Coverage initiated on Sarepta Therapeutics by RBC Capital Mkts Briefing.com
Jan-20-15 12:32PM  INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Sarepta Therapeutics, Inc. Business Wire
Jan-16-15 01:20PM  BioMarin CEO Angers Sarepta CEO With Slides Comparing Trial Data at The Wall Street Journal
Jan-15-15 04:30PM  Sarepta Starts Dosing in Duchenne Muscular Dystrophy Study - Analyst Blog Zacks
Jan-14-15 02:57PM  Sarepta's CEO can reverse the company's downward trend with a stellar presentation tomorrow at American City Business Journals +5.34%
12:43PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Sarepta Therapeutics, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of February 6, 2015 -- SRPT PR Newswire
08:30AM  Sarepta Therapeutics Announces First Patient Dosed in European Phase I/II Study of SRP-4053 in Duchenne Muscular Dystrophy Patients Business Wire
Jan-13-15 11:46AM  Chimerix tackles Ebola outbreak CNBC
Jan-12-15 04:23PM  Taking Stock: Winners and Losers, Stock of the Day at Bloomberg -14.62%
12:51PM  Sarepta Therapeutics (SRPT) Stock Hits One-Year Low Today After Eteplirsen Update at TheStreet
09:47AM  Sarepta Updates Eteplirsen Study Results, FDA Filing Still on for Mid Year at TheStreet
08:13AM  Sarepta Therapeutics Falls Following 6-Minute Walk Test Results Benzinga
07:09AM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or EDGAR Online
07:00AM  Sarepta Therapeutics Reports Long-Term Outcomes through 168 Weeks from Phase IIb Study of Eteplirsen in Duchenne Muscular Dystrophy Business Wire
Jan-07-15 10:47AM  Sarepta Therapeutics, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors Business Wire +5.81%
Jan-05-15 07:00AM  Sarepta Therapeutics to Present Company Overview at the 2015 33rd Annual J.P. Morgan Healthcare Conference Business Wire
Jan-02-15 12:39PM  SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Sarepta Therapeutics, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of February 6, 2015 Business Wire
Dec-31-14 04:30PM  Stull, Stull & Brody Announces the Investigation of Possible Breaches of Fiduciary Duties of Officers and Directors of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) GlobeNewswire
Dec-29-14 03:55PM  SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Sarepta Therapeutics, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of February 6, 2015 -- SRPT GlobeNewswire
12:45PM  Former CSO at Sarepta lands new job as head of Cambridge biotech startup at bizjournals.com
Dec-24-14 03:52PM  SECURITIES ALERT: Rosen Law Firm Reminds Sarepta Therapeutics, Inc. Investors of Important Deadline in Class Action Seeking to Recover Investor Losses - SRPT GlobeNewswire
Dec-16-14 05:46PM  SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Sarepta Therapeutics, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of February 6, 2015 -- SRPT Marketwired
Dec-09-14 05:35PM  EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Against Sarepta Therapeutics, Inc. to Recover Investor Losses -- SRPT GlobeNewswire +6.46%
03:32PM  SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Sarepta Therapeutics, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of February 6, 2015 -- SRPT GlobeNewswire
Dec-08-14 06:45PM  INVESTOR ALERT: Class Action Lawsuit Against Sarepta Therapeutics, Inc. Announced by Glancy Binkow & Goldberg LLP Business Wire
Dec-05-14 06:00AM  Biotech Stock Mailbag: Aethlon Medical, Oxigene, Sarepta at TheStreet
Dec-02-14 11:00AM  Sarepta DMD Community Update Call scheduled for 11:00 am ET today CCBN
Nov-24-14 05:24PM  It was another slow, low volume, lackluster trading session Yahoo Finance Blogs +5.59%
04:30PM  Sarepta Therapeutics to Host Webcast and Conference Call for the Duchenne Muscular Dystrophy Community on December 2, 2014 Business Wire
12:26PM  Midday movers: 3D Systems, Kate Spade, Nike & more at CNBC
12:20PM  BioMarin's Prosensa Buy: A 'Courageous' Acquisition? at Barrons.com
10:22AM  BioMarin Buys Prosensa Backs Up Troubled Drug at Investor's Business Daily
09:19AM  Stock Futures Trending Higher; Kate Spade Bags An Upgrade at Investor's Business Daily
07:00AM  Sarepta Therapeutics to Present Company Overview at Upcoming Conferences Business Wire
Nov-18-14 03:24PM  Robbins Arroyo LLP Is Investigating the Officers and Directors of Sarepta Therapeutics, Inc. (SRPT) on Behalf of Shareholders PR Newswire
09:15AM  Sarepta Therapeutics Announces First Patient Dosed in Confirmatory Study of Eteplirsen in Ambulant Patients with Duchenne Muscular Dystrophy Business Wire
Nov-14-14 06:16PM  INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Sarepta Therapeutics, Inc. (SRPT) To Contact The Firm PR Newswire
Nov-13-14 04:40PM  Sarepta Initiates Dosing for Study Evaluating Eteplirsen Zacks
10:21AM  A Day Of Reckoning Approaches For Merck And Its Critics at Forbes
Nov-12-14 05:15PM  Sarepta Therapeutics Announces First Patient Dosed in Study of Eteplirsen in Non-Ambulant Patients with Duchenne Muscular Dystrophy Business Wire
Nov-11-14 10:32AM  INVESTOR ALERT: Investigation of Sarepta Therapeutics, Inc. Announced by Glancy Binkow & Goldberg LLP Business Wire
Nov-10-14 04:14PM  SHAREHOLDER ALERT: Investigation on Behalf of Sarepta Therapeutics, Inc. Investors Announced by Law Offices of Howard G. Smith Business Wire
11:40AM  Sarepta Q3 Loss Narrower-Than-Expected, Eteplirsen in Focus Zacks
Nov-09-14 07:09PM  10-Q for Sarepta Therapeutics, Inc. Company Spotlight
Nov-06-14 08:00AM  Sarepta Therapeutics Inc Earnings Call scheduled for 8:00 am ET today CCBN +7.19%
07:51AM  Sarepta Therapeutics tops 3Q profit forecasts AP
07:09AM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an EDGAR Online
07:07AM  Q3 2014 Sarepta Therapeutics Inc Earnings Release - Before Market Open CCBN
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. Its lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development stage for the treatment of individuals with Duchenne muscular dystrophy (DMD), a rare genetic muscle-wasting disease caused by the absence of dystrophin. The company also focuses on developing therapeutics for the treatment of drug-resistant bacteria, Becker muscular dystrophy, progeria, adult onset pompe, lupus and graft-versus-host diseases; and other rare, genetic, anti-infective, neuromuscular, and central nervous system diseases. The company is also involved in developing treatments that are in Phase I clinical trials for infectious diseases, including AVI-7288 for Marburg virus; and AVI-7100 for H1N1 influenza virus. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kaye Edward M. MDSVP & Chief Medical OfficerFeb 27Buy11.828009,4521,311Mar 03 06:48 PM
Christopher Nishan GarabedianPresident and CEOFeb 27Buy11.828009,45229,552Mar 03 06:47 PM